secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001645113-26-000018
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure reports Q4 2025 revenues up 8% to $174M; FDA approves Optune Pax for pancreatic cancer
--------------------------------------------------------------------------------

- FDA approved Optune Pax for locally advanced pancreatic cancer in Feb 2026; expands addressable market significantly.
- Q4 2025 net revenue $174.4M (+8% YoY); full year $655.4M (+8%). Q4 net loss $24.5M ($0.22 loss per share).
- 2026 guidance: revenue $675-705M; Adjusted EBITDA ($20M)-$0M; Optune Lua/Pax revenue $15-25M.
- Frank Leonard appointed CEO Dec 2025; CMO Nicolas Leupin resigned Feb 2026; CMS billing privileges reinstated.
- Active patients on TTFields therapy globally totaled 4,620 at Dec 31, 2025; GBM prescriptions up 6%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000018/0001645113-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000018/nvcr-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer